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therapy with everolimus versus BSC alone from the Canadian societal perspective.
METHODS: A Markov model simulated 2 hypothetical patient cohorts (everolimus
versus BSC alone) from the time of initial treatment throughout the 6-year time
horizon. The cost-effectiveness of everolimus was calculated in terms of cost per
life-years gained (LYG) as well as cost per quality-adjusted life year (QALY) gained.
Health state transition probabilities were derived directly from the RECORD-1 sub-
group analysis; costs and health state utility values were obtained from literature.
The analysis was performed from a societal perspective; as such, direct medical
costs and indirect costs associated with productivity loss due to morbidity or future
income loss attributed to early mortality were included. A sensitivity analysis from
the payer’s perspective was additionally performed. Outcomes and costs were dis-
counted at a 5% annual rate. RESULTS: Treatment with everolimus produced an
estimated gain over BSC alone of 0.643 LYG (0.455 QALYs) at an incremental cost of
$22,074. The deterministic analysis resulted in incremental cost-effectiveness ra-
tios (ICERs) of $34,326/LYG and $48,507/QALY. The payer’s perspective sensitivity
analysis resulted in ICERs of $48,670/LYG and $68,777/QALY. According to the prob-
abilistic sensitivity analysis, given a threshold of $100,000/QALY, the probability
that everolimus was cost-effective, from a societal perspective, was 100%.
CONCLUSIONS: Results of this analysis suggest that, from a Canadian societal
perspective, everolimus is a cost-effective alternative to BSC alone when treating
mRCC patients whose disease fails on one prior VEGF-TKI treatment.
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OBJECTIVES: Colorectal cancer (CRC) is the third most frequent worldwide and
about 28,110 new cases were expect for Brazil in 2010. Two biologic agents are
approved for treatment of mCRC in Brazil: cetuximab, exclusively for K-RAS wild-
type patients and bevacizumab, for both K-RAS types. We aimed to compare costs
and outcomes of bevacizumab versus cetuximab in first-line treatment of mCRC,
both in combination with FOLFIRI from a private payer perspective in Brazil.
METHODS: In the absence of head-to-head trials comparing BevFOLFIRI and
CetFOLFIRI, an adjusted indirect comparison was conducted using Bucher-
method. Hazard ratios (HRs) from 3 studies: BICC-C(part II) comparing BevFOLFIRI
vs BevIFL; AVF2107g comparing BevIFL vs IFL; and CRYSTAL comparing
CetFOLFIR versus FOLFIRI; were utilized. An illness-death Markov model was
enhanced. Risks for progression and mortality were derived from Weibull regres-
sion model (assuming deaths conditional upon prior progression). Natural mortal-
ity rates were applied according to IBGE life table. Only direct costs were considered
for patients with 1,78m2 and 70Kg. Ex-factory prices were obtained from official
public sources. Time-horizon was two years according to natural history of the
disease. Utilities were derived from international sources; discounting was 5% for
costs and outcomes, according to local guidelines. A probabilistic sensitivity anal-
ysis (PSA) was conducted in order to evaluate the robustness of results. Non-sta-
tistically significant HR 95%-CIs were exploited in PSA. RESULTS: Results of the
analysis suggest BevFOLFIRI combination is less costly compared to CetFOLFIRI
($Brz216,838.38 vs. $Brz276,770.15) and a trend towards improved effectiveness
with BevFOLFIRI (OS 20.1 vs. 16.60 months; QALYs 1.1 vs. 0.9) in first-line treat-
ment of mCRC. PSA portends that BevFOLFIRI is dominant over CetFOLFIRI
(93,44% of iterations BevFOLFIRI prolonged OS, being less costly). CONCLUSIONS:
Based on current available data, analysis suggest BevFOLFIRI presents lower costs
and better efficacy than CetFOLFIRI for treatment of first-line mCRC from a pri-
vate payer perspective in Brazil.
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OBJECTIVES: To determine the cost-effectiveness of erlotinib compared with do-
cetaxel every 3 weeks (D3W) or weekly (DW) or pemetrexed in second line treat-
ment for patients with advanced or metastatic NSCLC, from the Brazilian Private
Healthcare System perspective. METHODS: The analysis is based on a three stage
Markov model to estimate costs and consequences of treatments over 2 years.
Epidemiological and efficacy data were derived from a systematic literature search.
Indirect network meta-analysis assessed the relative efficacy of the compared
treatments. The survival curves were modeled by fitting a Weibull distribution.
Only direct medical costs were considered: Drug costs, daily hospital admission
rates, procedures and laboratory test unit cost were obtain from Brazilian official
databases of private healthcare system fees. Costs and benefits were discounted at
5% yearly and reported in 2010 Brazilian currency (BRL). Outcomes were expressed
as progression-free survival (PFS; months), overall survival (OS; months) and qual-
ity adjusted life years (QALY). Probabilistic sensitivity analysis (PSA) was conducted
to assess model robustness.RESULTS:Through the systematic literature review we
identified a network meta-analysis performed by Hawkins et al comparing BR21,
JMEI, TAX 317, ISEL, INTEREST and SIGN trials that formed the body of clinical data
for the analysis. The analysis showed higher clinical benefits and lower average
costs for erlotinib (9.73 OS; 4.24 PFS; 0.25 QALY; R$40,471) than D3W (8.49 OS; 3.21
PFS; 0.21 QALY; R$47,180) or DW (8.49 OS; 3.21 PFS; 0.21 QALY; R$56,549) or pem-
etrexed (8.49 OS; 3.31 PFS; 0.21 QALY; R$60,151), showing the dominance of erlo-
tinib related to compared treatments. PSA demonstrated that in 86%, 98% and 97%
of the simulations erlotinib was dominant compared to D3W, DW and pemetrexed.
CONCLUSIONS: This analysis portends that Erlotinib could be considered as a
dominant treatment strategy in 2nd line mNSCLC compared to docetaxel or pem-
etrexed under the Brazilian Private Healthcare System perspective.
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OBJECTIVES: The optimal intensity of conditioning prior to allogeneic hematopoi-
etic stem cell transplants (HSCT) remains uncertain. We present the result of the
prospective socio-economic evaluation associated with a randomized study com-
paring two levels of intensity reduction.METHODS:We compare reduced intensity
conditioning regimen (RIC Fludarabine, oral myleran and anti-thymocyte-globu-
lin) and non myeloablative conditioning regimen (NMAC Fludarabine and total
body irradiation). Direct medical transplant costs were estimated by micro-costing
on the basis of patients’ CRF until 18 months after transplant. Costs of treatment of
progression were estimated within five years after transplant. Cost-effectiveness
analysis was performed using overall survival (OS) and disease free survival (DFS)
as endpoint. Health-related quality of life (HRQL) was measured prospectively by
the EORTC QLQ-C30 questionnaire administered seven days before transplant and
on days 30 80 180 and 360. Linear mixed model analysis was performed to
test whether there were differences in HRQL outcomes within and between the two
groups over time. GVHD occurrence was included in the model. RESULTS:A total of
139 patients with hematological malignancies were treated (RIC: N69; NMAC:
N70). Survival and DFS at one and five years were identical after RIC and NMAC.
The mean total cost per patient was not different between groups (83,656€ for RIC
vs. 72,592€ for NMAC, NS). This is related to decreased post graft costs for NMAC
(-22,815€, p0.002) being offset by increased costs of disease progression (11,750€,
p0.008). Using DFS as endpoint, the RIC is cost-effective: incremental cost-effec-
tiveness ratio978.64 [95%IC313.23-2447.91]. Using OS no differences were found
between the two groups. RIC had a stronger negative impact on patients’ HRQL
independently of GVHD. CONCLUSIONS: The results confirmed the relapse/toxic-
ity arbitrage associated with the choice of the allo-HSCT conditioning regimen.
Moreover, the importance of the choice of endpoints and follow-up times in the
economic evaluation of cancer treatment is highlighted.
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OBJECTIVES: Maintenance treatment with Rituximab of follicular lymphoma (FL)
patients responding to first-line induction therapy with R-CHOP, R-CVP or R-FCM,
increases progression-free survival (hazard ratio 0.55; 95% CI 0.44 to 0.68, P0.0001)
compared with observation. We performed a cost-effectiveness analysis of main-
tenance therapy in first line of the FL with rituximab, compared with the option of
wait and watch strategy. METHODS: We developed a Markov model of the FL,
with four health states (progression free survival in first or second line, progression
and death). The transition probabilities between states were obtained from clinical
trials PRIMA and EORTC 20981. Health state utilities were obtained from literature.
The use of health resources, from the perspective of the National Health System
was estimated by a panel of Spanish onco-hematologist experts. Unitary costs (€ in
2010) were obtained from Spanish sources. Deterministic and probabilistic analy-
ses were performed. RESULTS: In the deterministic base case analysis, for a time
horizon of 30 years, the incremental cost per life year gained (LYG) and quality-
adjusted life-years (QALYs) gained, was €5663 and €6253 respectively. The sensi-
tivity analyses confirmed the stability of the base case for time horizons of 10 and
20 years and various statistical distributions (Weibull, exponential, log-logistic,
log-normal, Gompertz, and gamma) ranging between €4222 and €8766.
CONCLUSIONS: Compared with observation, rituximab maintenance treatment of
the FL that responds to inmunochemotherapy induction in first line, is a cost-
effective strategy.
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OBJECTIVES: Combinations of chemotherapy and monoclonal antibodies (MAbs)
against the vascular endothelial growth factor (bevacizumab) and the epidermal
growth factor receptor (cetuximab) have been shown to improve the clinical out-
come of patients with mCRC. Little is known about the economic implications of
their use. The aim of this analysis was to evaluate the cost, clinical- and cost-
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effectiveness of adding the MAbs cetuximab or bevacizumab to chemotherapy in
the first-line treatment of mCRC patients with KRAS wild-type tumours, from the
UK (UK) NHS perspective. METHODS: A semi-Markov model was developed to
simulate patient outcomes and costs for first and subsequent lines of treatment
including long-term survival after a curative resection of liver metastases. Data for
progression-free survival, resection rates and other model parameters were mainly
derived from the CRYSTAL and NO16966 phase 3 studies. The long-term benefits of
surgery were estimated from a consecutive series of 1439 patients. Resource use
included drugs, physician visits, scans, hospitalizations and treatment of adverse
events. Extensive sensitivity analyses were undertaken to explore the robustness
of the results. RESULTS: In the base case, the estimated mean life expectancy for
cetuximab- and bevacizumab-containing regimens was 3.22 and 2.31 years (all
undiscounted) respectively. The incremental cost-effectiveness ratio (ICER) for
FOLFIRIcetuximab compared with FOLFIRI alone was £30,665 per quality-ad-
justed life year (QALY) and £17,626 per QALY compared with
FOLFOXbevacizumab. The ICER is mainly driven by the number of patients be-
coming resectable and the acquisition cost for each antibody. CONCLUSIONS: This
analysis suggests that cetuximab in combination with FOLFIRI is the most effective
treatment regimen compared with FOLFOXbevacizumab or chemotherapy alone
for patients with KRAS wild-type tumours. The incremental cost-effectiveness ra-
tios of cetuximab in combination with chemotherapy compared with chemother-
apy alone, and bevacizumab-containing regimens are within the commonly ac-
cepted threshold for cost-effectiveness in the UK.
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OBJECTIVES: PFS is an important endpoint in advanced NSCLC as it permits earlier
assessment of treatment benefit compared to overall survival (OS) and is not influ-
enced by subsequent treatment lines. Multiple treatment strategies have demon-
strated PFS benefits in solid tumor oncology, but the economic and humanistic
value of improved PFS remains unclear. METHODS: We developed a literature-
based, 3-state (progression-free, disease-progression, death) Markov model de-
signed to estimate clinical and economic outcomes associated with 2nd-line treat-
ment from a US-payer perspective. Modeled treatments included a commonly used
FDA-approved epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) and an equivalent hypothetical intervention with theoretical improvements
applied to quantify value of PFS gains. In base-case, we assumed 20% PFS improve-
ment for intervention and no differences in OS and tolerability profiles or costs
between comparators. Model parameters were pulled from published sources and
included OS, PFS, adverse event rates, health-state utilities, dosing, and costs.
Costs (2010 USD) and effects were discounted 3%. RESULTS: In base-case, projected
total lifetime discounted costs, PFLYs and QALYs were higher for intervention
($30,791; 0.53 PFLY; 0.32 QALY) vs. EGFR-TKI ($26,705; 0.43 PFLY, 0.30 QALY). Sce-
nario analyses identified two major determinants of costs-effectiveness in our
model: PFS improvements accompanied by quality of life (QoL) improvements and
post-progression treatment cost savings. Applying a range of QoL improvements
(10%-30%) resulted in increased lifetime QALYs for intervention (0.35-0.39) such
that ICER was $50,000/QALY with 25% QoL improvements. For QoL improve-
ments 25%, cost-effectiveness can be achieved with post-progression cost
savings. CONCLUSIONS: An intervention conferring PFS improvements may be
cost-effective if modest treatment-related QoL improvements and/or post-pro-
gression cost savings are realized. New and emerging treatments for NSCLC ther-
apies that demonstrate improvement in one or both of these measures and/or OS
and safety benefits will probably be competitive as payers start to weigh cost-
effectiveness measures in coverage decisions.
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OBJECTIVES: Assess clinical and economic outcomes of vaccination (Va) with hu-
man papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine (16/18Vac) added to
screening programmes (Scr) in cervical cancer (CC) prevention, from the National
Healthcare System perspective. METHODS: A lifetime Markov cohort model with
yearly cycles was populated using national epidemiological, cost and treatment
data to simulate the natural history of HPV and assess the effect of VaScr strat-
egies versus Scr alone. Base case considers vaccinating a cohort of 206.788 girls
aged 11, 80% of vaccine coverage and screening each 3 years from age 25 to 65.
Efficacy of 16/18Vac was 95% against HPV-16/18 and cross-protection against 5
oncogenic non-vaccine types of 68%. Outcomes measured were number of CC
cases, CC deaths, quality adjusted life years (QALYs), costs and incremental cost-
effectiveness ratio (ICER) between both strategies. The model also tested a broader
campaign vaccinating both 11 & 18 years old during 7 years (100,000 individuals per
cohort and year) versus vaccination girls aged 11 only. A discount rate of 3% over
costs and outcomes was applied. Sensitivity analyses were performed to assess
influence of different parameters.RESULTS: Base case scenario would avoid 817 CC
cases and 188 deaths (undiscounted) versus Scr alone and generate 1,018 additional
QALYs, resulting in an ICER of € 29.295/QALY (discounted). Vaccination of the co-
horts aged 11 & 18 would avoid 2,448 CC cases and 602 CC deaths (undiscounted)
compared with vaccination only of the 11 years cohort, and represents an ICER of
28,931€/QALY (discounted). Sensitivity analysis shows more favourable cost-effec-
tiveness with higher coverage. CONCLUSIONS: HPV vaccination with 16/18Vac
added to current screening programmes in Spain is a cost-effective strategy. More
favourable cost-effectiveness results may be obtained by expanding vaccination to
18 years old women and increasing vaccination coverage. Results are in accordance
with other studies published at national level.
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OBJECTIVES: Zoledronic acid (ZOL) is the only approved bisphosphonate for SRE
prevention in hormone-refractory prostate cancer (mHRPC). However, in the UK
(UK), 19% and 4% of metastatic, mHRPC patients, do not receive bisphosphonates or
receive non-approved/unproven bisphosphonates (i.e., pamidronate [PAM]), re-
spectively for the prevention of skeletal-related events (SREs). This analysis sought
to estimate, from a UK payer perspective, the cost effectiveness of providing ZOL to
those mHRPC patients not receiving ZOL. METHODS: This analysis was based on
the results of a published randomized phase III clinical trial wherein mHRPC pa-
tients received 15 months of ZOL or placebo (PBO) (Saad et al, 2002). Since PAM
has been shown to be no different than PBO in mHRPC in a pooled analysis of two
trials (Small et al 2003) (i.e., 25% of subjects experienced an SRE at 6 months), the
PBO cohort data from the ZOL trial was as a surrogate for PAM data in the absence
of a direct comparison of ZOL versus PAM (or other bisphosphonates). Costs were
estimated using hospital tariffs and published/internet sources. Quality adjusted
life years (QALYs) gained were based on a previously published analysis of the Saad
et al (2002) data. Survival was assumed to be identical for both groups. RESULTS:
Compared with the use of PAM/PBO, treatment with ZOL (at list price of £174.14/
infusion vs £80/infusion with PAM) resulted in increased QALYs (0.03566/pt),
fewer SREs (-0.8314/pt, i.e., 0.8315 vs 1.6629), and fewer SRE-related costs (-£1,639/
pt, i.e., £2,004 vs. £3,643). Total costs were higher with ZOL (£702/pt). ZOL cost
£19,689/QALY. CONCLUSIONS: The use of ZOL for the prevention of SREs in UK
patients with bone metastases secondary to mHRPC is cost effective relative to
providing no or unapproved bisphosphonates.
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OBJECTIVES: This study aims to identify whether it is desirable to recommend
low-dose aspirin as chemoprevention therapy for colorectal cancer in addition to
routine screening through cost-effectiveness review for general population in
Korea. METHODS: A Markov model was constructed to simulate the disease natu-
ral history of colorectal cancer with routine screening and additional chemopre-
vention by low dose aspirin. The model evaluated hypothetical cohorts of each
100,000 men and women aged from 50 to 70 years old stratified as 5-years interval.
The analysis adopted a social perspective and all costs and outcomes were dis-
counted at 5% for 30 years. The result was presented as the incremental cost per
QALY gained. Uncertainty was explored with deterministic and probabilistic sen-
sitivity analysis. RESULTS: The analysis showed that the use of low dose aspirin in
addition to routine screening comparing to the screening alone is likely to result in
a incremental cost per QALY of around 3,000,000 KRW/QALY to 8,700,000 KRW/
QALY for men over than 50 years old and of around 4,700,000 KRW/QALY to
12,000,000 KRW/QALY for women over than 55 years old. The deterministic sensi-
tivity analysis for uncertain parameters demonstrated that this analysis results
were robust. Assuming a willingness-to-pay threshold of 15,000,000 KRW per QALY
gained, the probabilistic sensitivity analysis suggested that low dose aspirin che-
moprevention is more net benefit than screening alone for both men over than 50
years old and women over than 55 years old. However, there was considerable
uncertainty in the current evidence available. CONCLUSIONS: Low dose aspirin
appears to be cost-effective regardless of the wide distribution of ICER as chemo-
prevention of colorectal cancer coupled with screening comparing to the screening
alone for the men over than 50 years old and women over than 55 years old.
Therefore, low dose aspirin can be recommended as chemoprevention therapy in
Korean population.
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OBJECTIVES: to assess the epidemiological and economic impact of a quadrivalent
human papillomavirus (HPV) types 6/11/16/18 vaccination in Turkey. METHODS: a
published mathematical model of the transmission dynamics of HPV infection and
disease was adapted for Turkey. The model captured direct protective effects of
vaccination and indirect effects (herd immunity). Model inputs were used from
Turkey when available; otherwise, the default values in the original model were
used. The vaccination strategy included HPV vaccination of 12-year-old girls com-
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